Zecuity, sumatriptan skin patch can cause burns, is pulled off the market

June 11, 2016

Zecuity, a transdermal sumatriptan patch has been reported to cause skin burns and scarring, according to the FDA. The FDA has started an investigation, but the manufacturer, Teva Pharmaceuticals has decided to pull the product off the market.

This is not a major loss for migraine sufferers since we now have four other ways to deliver sumatriptan (Imitrex) – tablet, injection, nasal spray, and nasal powder.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe